Amgen (AMGN) has been receiving substantial attention from both investors and brokerages. This biotechnology company has seen a significant rise in its share price over the past year, with Barclays starting coverage of the company with an equal-weight recommendation. Notable investment groups, including the Neuberger Berman Group and Munich Reinsurance Co, have modified the number of shares they hold, hinting at dynamic market movements. Meanwhile, Amgen maintains a steady quarterly dividend of $2.52 per share, changing narratives around its capital allocation. Analysts suggest that its investment story has shifted due to elements like the issuance of a $4 billion long-dated bond. Despite debate over its latest clinical trials, some analysts believe Amgen's strong Q4 portfolio momentum warrants reassessment of its valuation. Its recent robust performance has triggered increased price targets from HSBC and investment companies like UBS and BMO Capital. On the production front, the company announced a $650 million expansion in US manufacturing operations creating hundreds of new jobs. Amid all, there is consensus among analysts that its cholesterol drug and other ongoing projects are game-changers. Hence, the company's overall outlook points towards future growth potential.
Amgen AMGN News Analytics from Fri, 01 Aug 2025 07:00:00 GMT to Sat, 07 Mar 2026 12:12:34 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor -4
